ArticleBlood2018
Registry-linked trialOpen access · bronzeAbstract readCase Reports
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00137111 (Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia), which is not on this map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Who cites it
35 citing papers in PubMed, 76 citations in OpenAlex.
- From the bench of molecular understanding to the bedside of optimal therapy forEJC paediatric oncology · 2025Article
- Long-read sequencing unmasks a cryptic three-way translocation resulting in an ETV6::PDGFRB fusion.Molecular cytogenetics · 2025Article
- Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy.Annals of hematology · 2025Article
- Review
- From multi-omics to functional validation: the PTMRS stratifies TME and positions PDGFRB in CRC biology.Frontiers in immunology · 2025Article
- Clonal evolution of the 3D chromatin landscape in patients with relapsed pediatric B-cell acute lymphoblastic leukemia.Nature communications · 2024Article
- Proteomic analysis of pleomorphic dermal sarcoma reveals a fibroblastic cell of origin and distinct immune evasion mechanisms.Scientific reports · 2024Article
- Article
- Mitotic catastrophe heterogeneity: implications for prognosis and immunotherapy in hepatocellular carcinoma.Frontiers in immunology · 2024Article
- Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children's Cancer Group study ALL-2015.Annals of hematology · 2023Article
- Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.Nature communications · 2023Article
- [ST13-PDGFRβ positive acute myeloid leukaemia: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Review
- Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.Annals of hematology · 2023Review
- [Optimized treatment of childhood B-lineage acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023Article
- CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL.Biomarker research · 2023Article
- Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.Signal transduction and targeted therapy · 2022Review
- Review
- Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis.Nature cell biology · 2022Article
- Circulating Tumor DNA in Pediatric Cancer.Frontiers in molecular biosciences · 2022Review
- Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia.Computational and mathematical methods in medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 7 institutions in 3 countries.
Yingchi ZhangState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Yufeng GaoKey Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Hui ZhangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Jingliao ZhangState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Fuhong HeKey Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Aleš HnízdaInstitute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic; and.
Maoxiang QianDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Xiaoming LiuState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Yoshihiro GochoDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Ching-Hon PuiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Tao ChengState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Qianfei WangKey Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Jun J YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Xiaofan ZhuState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Xin LiuKey Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
St. Jude Children's Research Hospital · USBeijing Institute of Genomics · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese Academy of Sciences · CNInstitute of Hematology & Blood Diseases Hospital · CNCzech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZUniversity of Chinese Academy of Sciences · CN
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MCPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1MNCI NIH HHS P30 CA021765NIGMS NIH HHS P50 GM115279
Abstract
Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) comprises ∼10% to 15% of childhood ALL cases, many of which respond exquisitely to tyrosine kinase inhibitors (TKIs), for example, imatinib in
Indexed as
MutationAngiogenic ProteinsAntineoplastic AgentsCell Line, TumorChild, PreschoolDrug Resistance, NeoplasmHumansMaleOncogene Proteins, FusionPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor betaRecurrenceTreatment OutcomeWhole Genome SequencingAGGF1 protein, humanAngiogenic ProteinsAntineoplastic AgentsOncogene Proteins, FusionPDGFRB protein, humanProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT00137111ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.